文献速递膀胱癌与上尿路尿路上皮癌

内镜治疗大体积多灶性上尿路尿路上皮癌的肿瘤学与手术结局

Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2020-11-20

该回顾性研究纳入59例(62个肾单位)低级别上尿路尿路上皮癌患者,采用双激光内镜治疗并严格输尿管镜随访。中位随访22个月,局部复发率74.1%,进展率6.4%,无进展生存率93.2%。肾内肿瘤和多灶性是局部复发的显著预测因素。

要点

  • 内镜治疗大体积多灶性低级别上尿路尿路上皮癌可行,短期肿瘤学 outcomes 良好。
  • 肾内肿瘤和多灶性与更短的局部复发时间显著相关。
  • 无进展生存率达93.2%,进展率低,但局部复发常见。

核心结论

  • 输尿管镜治疗大体积、多灶性低级别上尿路尿路上皮癌可行,不涉及显著并发症,短期肿瘤学结局良好,无进展生存率93.2%。

研究设计与样本

  • 回顾性队列研究,纳入2014至2019年在本机构接受内镜治疗的低级别上尿路尿路上皮癌患者,共59例(62个肾单位)。

主要发现

  • 中位随访时间22个月(IQR 11-41),中位输尿管镜检查次数5.5次(4-9次)。
  • 46个肾单位(74.1%)出现局部复发,中位复发时间6.5个月。
  • 4例患者(6.4%)出现疾病进展并转根治手术,其中2例病理进展,2例快速高体积局部复发,1例 later 出现转移。
  • 无进展生存率为93.2%。
  • 肾内肿瘤位置(p=0.03,HR 1.95)和多灶性(p=0.005,HR 3.25)显著预测局部复发时间,但无因素预测进展时间。

临床怎么用

  • 对于低级别上尿路尿路上皮癌,尤其是大体积或多灶性肿瘤,内镜治疗可作为可行选择,但需严格输尿管镜随访。
  • 肾内肿瘤和多灶性患者局部复发风险更高,应加强随访监测。

局限性

  • 回顾性研究设计,样本量较小(59例),随访时间较短(中位22个月),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We reviewed the oncologic and surgical outcomes of endoscopic treatments for low grade upper tract urothelial carcinoma, and assessed the prognostic significance of tumor size, location and multifocality. MATERIALS AND METHODS: We retrospectively reviewed all patients who underwent endoscopic treatment for low grade upper tract urothelial carcinoma at our institution between 2014 and 2019. Tumors were treated with a dual laser generator, which alternately produces holmium and neodymium lasers. A stringent ureteroscopic followup protocol was conducted. We looked for an association between outcome and tumor size, location or multifocality, and for predictive factors for time to local recurrence and progression. RESULTS: The cohort included 59 patients (62 renal units), 27% of tumors were multifocal and 40% were >2 cm. The median followup time was 22 months (IQR 11-41), and the median number of ureteroscopies was 5.5 (4-9). Local recurrence was observed in 46 renal units (74.1%) at a median of 6.5 months after initial surgery. Four patients (6.4%) developed disease progression and were referred for radical surgery: 2 had pathological progression and 2 had a rapid and high volume local recurrence, and 1 later developed metastatic disease. The progression-free rate was 93.2%. Tumor location in kidney (p=0.03, HR 1.95) and multifocality (p=0.005, HR 3.25) significantly predicted time to local recurrence. No factor predicted time to progression. CONCLUSIONS: Ureteroscopic treatment of large, multifocal, low grade upper tract urothelial carcinoma is feasible, does not involve significant complications and has good short-term oncologic outcomes, with a 93.2% progression-free survival rate. Tumors located in the kidney and multifocality yielded shorter time to local recurrence but not progression.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Shvero A, Abu-Ghanem Y, Laufer M, et al. Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma. J Urol. 2020. PMID: 33216692. doi:10.1097/JU.0000000000001505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。